We sought to quantify maternal plasma exosome-derived miRNAs known to target the nitric oxide (NO) pathway as surrogate biomarkers of cervical remodeling in women on 17P for recurrent PTB prevention. STUDY DESIGN: Prospective cohort of women with 1 prior SPTB receiving 17P in a subsequent singleton, non-anomalous gestation at a single tertiary institution. Maternal plasma was collected at 12-24 wks. Exosomes were separated from plasma by ultracentrifugation. We quantified the expression of 3 NO pathway-controlling miRNAs (miR-543, miR-940, miR-2143) using TaqMan assays. Women were classified as 17P non-responders (recurrent SPTB <34 wks) or 17P responders (delivery 37 wks), and miRNA expression compared. The secondary outcome was recurrent PTB <24 wks. A statistical cut point was calculated for each miR to determine the optimal sensitivity and specificity of the miR in SPTB prediction. Women were classified as having a 'high' or 'low' result for each miR based on this cut point. Data were analyzed using t-test, Fisher's exact, ANOVA, and Kaplan-Meier curves. RESULTS: 24 women with a prior SPTB on 17P were included; twelve 17P non-responders and twelve 17P responders. Maternal plasma was sampled at a median 15.9 (IQR 14.9-18.1) wks for 17P responders and 20.0 (IQR 18.2-22.3) wks for 17P non-responders, p¼0.024. 17P nonresponders delivered at a median 25.4 (IQR 22.2-30.4) wks; 5/12 delivered <24 wks. Absolute expression of each miR did not vary by 17P responder status. However, expression of miR-543 was increased in those with recurrent PTB <24 wks compared with women delivering at term (6.8 vs. 5.1, p¼0.009), and those with high miR-543 expression delivered earlier (median 25.1 vs. 34.0 wks, p¼0.013), Figure. There was also a trend towards earlier delivery with high expression of miR-2143 (median 24.0 vs. 37.3 wks, p¼0.053), Figure. Prediction models for 17P nonresponse combining miR-543 and miR-2143 expression and controlling for sample GA had an AUC of 0.83 (95% CI 0.66 e 1.0), PPVof 67%, and NPV of 67%. Prediction improved when considering only women delivering 24 wks (AUC 0.93, 95% CI 0.81-1.0, PPV 75%, NPV 85%). CONCLUSION: The expression of miR-543 derived from circulating plasma exosomes differentiates between 17P responders and nonresponders. miR-543 targets 29% of NO pathway genes. These studies should be validated using a larger sample size and further interrogate the role of the NO pathway and response to 17P.
